NCT01493024View on ClinicalTrials.gov

Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions
HyperkalemiaChronic Kidney DiseaseKidney Dysfunction
Interventions
DRUG

Zirconium silicate (ZS)

Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.

DRUG

Placebo

Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.

Trial Locations (9)

32132

Riverside Clinical Research, Edgewater

32806

Compass Research Phase 1, LLC, Orlando

33169

Elite Research Institute, Inc., Miami

34491

Lakeview Medical Research, Summerfield

66219

Johnson County Clin-Trials, Lenexa

77099

Southwest Houston Research, Ltd, Houston

78215

Renal Associates, P.A., San Antonio

85284

Southwest Clinical Research Institute, Tempe

92626

West Coast Clinical Trials, Costa Mesa

All Listed Sponsors
lead

ZS Pharma, Inc.

INDUSTRY

NCT01493024 - Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia | Biotech Hunter | Biotech Hunter